HR Execs on the Move

Biogen

www.biogen.com

 
We are a biotechnology leader that discovers, develops and delivers innovative therapies to improve the lives of patients with neurodegenerative diseases, hematologic conditions and autoimmune diseases. Patients worldwide benefit every day from our medicines for multiple sclerosis (MS) and hemophilia.
 Founded in 1978, we are one of the world’s oldest independent biotechnology companies. Our development pipeline is focused on areas of high unmet medical need, as we pursue new therapies for patients suffering from diseases with few or no treatment options. These include programs for secondary progressive MS, Alzheimer’s Disease, spinal muscular atrophy, lupus and amyotrophic lateral sclerosis (ALS), amongst others. With ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.biogen.com
  • 225 Binney Street
    Cambridge, MA USA 02142
  • Phone: 781.464.2000

Executives

Name Title Contact Details
Charles Rathmann
 Regional Sales Director Profile
Carlos Morris
 Regional Sales Director Profile
Glenna Griffin
 Director, Talent and Organizational Performance Profile
Jamie Paul
 Associate Director, US Commercial Finance Profile
Kedhar Thiruvalam
 Associate Director, R&D Program Leadership and Strategic Innovation Profile

Similar Companies

Libra Therapeutics

Libra Therapeutics is focused on developing novel disease-modifying therapeutics that can restore the cellular balance disrupted in neurodegenerative diseases.

BIND Biosciences

BIND Biosciences, Inc. is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

ElevateBio

ElevateBio is accelerating the future of biotechnology. We have a launched a revolutionary new model that integrates innovators, infrastructure and capital to effectively develop cell, gene and related therapies for patients with severe and life-threatening disorders.

GangaGen Inc

GangaGen Inc is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Joule Unlimited

Joule has pioneered a CO2-to-fuel production platform, effectively reversing combustion through the use of solar energy. Free of feedstock constraints and complex processing, this platform can achieve unrivaled scalability, volumes and costs without the use of any agricultural land, fresh water or crops. Unlike products derived with complexity from petroleum or biomass, Joule Sunflow® products are produced in a direct, continuous process from abundant resources. The novel CO2-to-liquids conversion requires only sunlight, non-potable water and engineered bacteria that function as living catalysts to produce specific products, including ethanol and hydrocarbon fuels that are inherently compatible with existing infrastructure. Joule’s highly efficient process and production system are well suited for deployment around the world, unhindered by land or resource constraints. This uniquely modular system can achieve replicable productivity, whether installed across 100 or 1,000 acres, mitigating scale-up risks and ensuring stability of supply. At full-scale commercialization in ideal locations, the company ultimately targets 25,000 US gallons of Joule Sunflow®-E (solar ethanol) or 15,000 US gallons of Joule Sunflow®-D (solar diesel) per acre annually, for approximately $1.20/US gallon ($50/barrel). Joule has successfully pilot-tested its platform for over two years, initiated demonstration-scale operations, and assembled a specialized team to lay the groundwork for commercial deployment. The company is moving rapidly to commercialize Joule Sunflow-E, with Joule Sunflow-D and additional hydrocarbon fuels to follow. Joule is privately held and has raised approximately $200 million in funding to date. The company was founded within Flagship VentureLabs™, and operates out of Bedford, Massachusetts and The Hague, The Netherlands, with production operations in Hobbs, New Mexico.